CN85102133A - 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 - Google Patents
2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 Download PDFInfo
- Publication number
- CN85102133A CN85102133A CN198585102133A CN85102133A CN85102133A CN 85102133 A CN85102133 A CN 85102133A CN 198585102133 A CN198585102133 A CN 198585102133A CN 85102133 A CN85102133 A CN 85102133A CN 85102133 A CN85102133 A CN 85102133A
- Authority
- CN
- China
- Prior art keywords
- nitroxymethyl
- chloropyridine
- occluded
- beta
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Abstract
在本申请中公开了2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物及其制备方法。其中2—硝基氧甲基—6—氯吡啶与β—环糊精的摩尔比在约1∶1和约3∶1之间。该吸留化合物是不挥发的,因此,为了制备药剂,要克服与2—硝基氧甲基—6—氯吡啶的挥发性有关的问题。本发明的方法是通过2—硝基氧甲基—6—氯吡啶与β—环糊精反应来完成的,或是通过两个化合物与少量的溶剂捏和,或是通过两个化合物在适宜的溶剂例如水中混合。然后该吸留化合物用常规的方法沉淀,分离和进一步纯化。
Description
本发明是关于2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物及其制备方法。
2-硝基氧甲基-6-氯吡啶是具有下面结构式的化合物,并用于医治血管病。
2-硝基氧甲基-6-氯吡啶是油性的和易挥发的物质。通常把这样的物质制成药剂是困难的。
为了克服上述困难通过深入的研究,本发明者发现用2-硝基氧甲基-6-氯吡啶与β-环糊精以摩尔比约为1∶1或3∶1的条件下,转变成吸留化合物可以克服上面的困难。
本发明不仅成功地解决了2-硝基氧甲基-6-氯吡啶粉剂制备的问题,而且成功地解决了防止挥发的问题。
本发明的方法是通过使2-硝基氧甲基-6-氯吡啶与β-环糊精反应来完成的。
吸留的方法包括几种改进。例如,有溶剂方法,包括宿主化合物和客体化合物同少量溶剂一起进行捏和的方法,等等。在这些方法中优先选用的是溶剂方法,该方法只需要在适宜溶剂中两种化合物相互混合。得到的吸留化合物用常规方法进行分离和纯化。例如,当吸留反应在水溶液中进行时,微溶于水的吸留化合物从反应混合物中沉淀出来。沉淀物可用常规的方法分离,例如用离心分离。这样分出的产物可用水洗纯化,从而除去了水溶性的β-环糊精或2-硝基氧甲基-6-氯吡啶。
上述方法得到的吸留化合物的特点在于防止了2-硝基氧甲基-6-氯吡啶的挥发。例如:从图5可明显的看出,图5表示2-硝基氧甲基-6-氯吡啶的残余百分数是时间的函数,在放置60分钟后,可保留100%的摩尔比为1∶1的2-硝基氧甲基-6-氯吡啶-β-环糊精吸留化合物或约87%摩尔比为3∶1的2-硝基氧甲基-6-氯吡啶-β-环糊精吸留化合物。而2-硝基氧甲基-6-氯吡啶本身在放置60分钟后,残余百分数为0%,由此清楚的看出显著地防止了2-硝基氧甲基-6-氯吡啶的挥发。
下面的实例是进一步说明本发明方法。
实例1
在5个离心分离管中分别用20ml蒸馏水溶解600mg β-环糊精。接着向5个离心分离管中分别加入50,100,200,300和400mg2-硝基氧甲基-6-氯吡啶,摇动离心分离该混合物,然后使其在室温下静置一夜,以便完全结晶。
过滤收集结晶体,用水洗涤,然后,空气干燥得到2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物。
制备2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的条件和在产物中的摩尔比见表1。
得到的吸留化合物有下列物理性质。
(ⅰ)在它的X射线粉末衍射图中,显示出峰值在约11.5°和约18.4°。这些都是2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的特性。
(ⅱ)在它的红外吸收光谱中(液体石蜡),显示在3300,1645,1586,1568,1459,1376,1330,1281,1158,1080,1022,1000,940和842Cm-1处有吸收。
(ⅲ)微溶于水。
这些产物的X-射线粉末衍射图在图1和图2表示,和红外吸收光谱在图3和图4表示。
图1和图2是按照本发明实例1中得到的吸留化合物的X射线粉末衍射图,即,摩尔比分别为1∶1和3∶1的2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的X射线粉末衍射图。图3和图4是本发明的吸留化合物其摩尔比分别为1∶1和3∶1时的红外吸收光谱。
图5说明了吸留化合物对2-硝基氧甲基-6-氯吡啶挥发性的影响。
Claims (2)
1、2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的制备方法,包括2-硝基氧甲基-6-氯吡啶与β-环糊精反应,该吸留化合物具有下列物理性质:
(i)在它的X射线粉末衍射图中,显示出2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物的特性峰值在11.5°,约17.2°和约18.4°。
(ii)在它的红外吸收光谱(液体石蜡)中,显示出在3300,1645,1586,1568,1459,1376,1330,1281,1158,1080,1022,1000,940和842Cm-1处有吸收。
(iii)微溶于水。
2、权项要求1的方法中,β-环糊精的水溶液与2-硝基氧甲基-6-氯吡啶混合。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58190345A JPS6081166A (ja) | 1983-10-11 | 1983-10-11 | 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN85102133A true CN85102133A (zh) | 1987-01-17 |
Family
ID=16256648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN198585102133A Pending CN85102133A (zh) | 1983-10-11 | 1985-04-01 | 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US4575548A (zh) |
EP (1) | EP0141300A3 (zh) |
JP (1) | JPS6081166A (zh) |
KR (1) | KR850003414A (zh) |
CN (1) | CN85102133A (zh) |
AU (1) | AU576521B2 (zh) |
CA (1) | CA1248523A (zh) |
DK (1) | DK461184A (zh) |
ES (1) | ES536654A0 (zh) |
FI (1) | FI843944L (zh) |
GR (1) | GR80531B (zh) |
HU (1) | HU194285B (zh) |
IL (1) | IL73076A (zh) |
NO (1) | NO843773L (zh) |
OA (1) | OA07832A (zh) |
PH (1) | PH20203A (zh) |
PT (1) | PT79320B (zh) |
ZA (1) | ZA847350B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034156A (ja) * | 1983-08-08 | 1985-02-21 | Hayashibara Biochem Lab Inc | エイコサペンタエン酸包接化合物及びこれを含有した飲食物 |
JPS60202115A (ja) * | 1984-03-27 | 1985-10-12 | Ichiro Shibauchi | エポキシ樹脂用硬化剤 |
ZA885069B (en) * | 1987-07-24 | 1989-03-29 | Fujisawa Pharmaceutical Co | Sustained-release percutaneous preparations |
US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
CA1321192C (en) * | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
EP1176792A1 (en) * | 2000-07-24 | 2002-01-30 | Alcatel | Method and apparatus for providing an all digital loop with power-optimised mode |
US20070009531A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
US20070010486A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US20070010485A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US20070010487A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US20070010478A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
US11812951B2 (en) | 2008-06-17 | 2023-11-14 | Apollo Endosurgery Us, Inc. | Endoscopic needle assembly |
CA2692211C (en) * | 2009-12-14 | 2011-09-13 | Cellresin Technologies, Llc | Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging |
PT2690951E (pt) | 2011-03-27 | 2015-11-25 | Cellresin Tech Llc | Composições de ciclodextrina, artigos, e métodos |
US10182567B2 (en) | 2011-03-27 | 2019-01-22 | Cellresin Technologies, Llc | Cyclodextrin compositions, articles, and methods |
US9320288B2 (en) | 2012-11-30 | 2016-04-26 | Cellresin Technologies, Llc | Controlled release compositions and methods of using |
US9421793B2 (en) | 2014-06-26 | 2016-08-23 | Cellresin Technologies, Llc | Electrostatic printing of cyclodextrin compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2959580A (en) * | 1956-10-17 | 1960-11-08 | Univ Minnesota | Formation of inclusion compounds |
CH445129A (fr) * | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
JPS56123912A (en) * | 1980-03-05 | 1981-09-29 | Nitto Electric Ind Co Ltd | Drug-containing tape preparation |
HU182217B (en) * | 1980-10-17 | 1983-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids |
JPS57142962A (en) * | 1981-02-28 | 1982-09-03 | Santen Pharmaceut Co Ltd | Cyclodextrin clathrate compound of sulfur-containing compound |
JPS6054304B2 (ja) * | 1981-10-16 | 1985-11-29 | 株式会社バコム | ジソピラミド包接化合物 |
US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
DK311683A (da) * | 1982-07-26 | 1984-01-27 | Fujisawa Pharmaceutical Co | Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser |
JPS6025967A (ja) * | 1983-07-21 | 1985-02-08 | Eisai Co Ltd | トリパミド包接化合物 |
DE3329517A1 (de) * | 1983-08-16 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate |
DE3337802A1 (de) * | 1983-10-18 | 1985-04-25 | Merck Patent Gmbh, 6100 Darmstadt | Pharmazeutische zubereitung |
-
1983
- 1983-10-11 JP JP58190345A patent/JPS6081166A/ja active Granted
-
1984
- 1984-09-18 ZA ZA847350A patent/ZA847350B/xx unknown
- 1984-09-20 NO NO843773A patent/NO843773L/no unknown
- 1984-09-21 AU AU33399/84A patent/AU576521B2/en not_active Ceased
- 1984-09-26 IL IL73076A patent/IL73076A/xx unknown
- 1984-09-26 US US06/654,471 patent/US4575548A/en not_active Expired - Fee Related
- 1984-09-26 DK DK461184A patent/DK461184A/da not_active Application Discontinuation
- 1984-09-28 CA CA000464361A patent/CA1248523A/en not_active Expired
- 1984-10-03 GR GR80531A patent/GR80531B/el unknown
- 1984-10-04 PT PT79320A patent/PT79320B/pt unknown
- 1984-10-08 FI FI843944A patent/FI843944L/fi not_active Application Discontinuation
- 1984-10-09 EP EP84112056A patent/EP0141300A3/en not_active Withdrawn
- 1984-10-10 HU HU843806A patent/HU194285B/hu not_active IP Right Cessation
- 1984-10-10 ES ES536654A patent/ES536654A0/es active Granted
- 1984-10-11 PH PH31326A patent/PH20203A/en unknown
- 1984-10-11 OA OA58409A patent/OA07832A/xx unknown
- 1984-10-11 KR KR1019840006284A patent/KR850003414A/ko not_active Application Discontinuation
-
1985
- 1985-04-01 CN CN198585102133A patent/CN85102133A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
PT79320A (en) | 1984-11-01 |
AU3339984A (en) | 1985-04-18 |
DK461184A (da) | 1985-04-12 |
NO843773L (no) | 1985-04-12 |
AU576521B2 (en) | 1988-09-01 |
EP0141300A2 (en) | 1985-05-15 |
JPS6245226B2 (zh) | 1987-09-25 |
ZA847350B (en) | 1985-10-30 |
ES8506758A1 (es) | 1985-08-01 |
DK461184D0 (da) | 1984-09-26 |
US4575548A (en) | 1986-03-11 |
OA07832A (fr) | 1986-11-20 |
JPS6081166A (ja) | 1985-05-09 |
HUT36832A (en) | 1985-10-28 |
GR80531B (en) | 1985-01-09 |
IL73076A (en) | 1988-05-31 |
EP0141300A3 (en) | 1986-01-29 |
HU194285B (en) | 1988-01-28 |
PH20203A (en) | 1986-10-20 |
KR850003414A (ko) | 1985-06-17 |
FI843944A0 (fi) | 1984-10-08 |
IL73076A0 (en) | 1984-12-31 |
CA1248523A (en) | 1989-01-10 |
ES536654A0 (es) | 1985-08-01 |
FI843944L (fi) | 1985-04-12 |
PT79320B (en) | 1986-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN85102133A (zh) | 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 | |
DE60209516T2 (de) | Prozess zur Herstellung kristalliner Partikel von Fluticason, Beclomethason, Salmeterol und Salbutamol | |
RU2126397C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ТРИГИДРАТА (2R, 3S)-3-ТРЕТ-БУТОКСИ-КАРБОНИЛАМИНО-2-ГИДРОКСИ-3- ФЕНИЛПРОПИОНАТА-4-АЦЕТОКСИ -2α- БЕНЗОИЛОКСИ -5β, 20-ЭПОКСИ -1,7β,10β- ТРИГИДРОКСИ-9-ОКСО- ТАКС-11-ЕН-13α-ИЛА | |
JP3511144B2 (ja) | 促進剤系の貯蔵安定性溶液 | |
DE60022147T2 (de) | Organophosphor- Zusammensetzung, Verfahren zur Herstellung einer Organophosphor-Verbindung, Polyester-Zusammensetzung und Verfahren zur Herstellung davon | |
JP2785018B2 (ja) | 二酸化第二セリウムをアルコール中に分散させてなるコロイド分散体の製造方法 | |
Jernakoff et al. | Hydrolysis of the metal-chloride bonds in (. eta. 5-C5Me5) TaCl4 leading to stepwise formation of binuclear and trinuclear tantalum oxide clusters | |
DE69226578T2 (de) | Production eines Zellulosederivates | |
DE2802485A1 (de) | Koordinationskomplexe von metallhalogeniden mit siliciumhaltigen verbindungen und deren verwendung | |
JPS63280100A (ja) | 結晶性ヒトプロインシュリンおよびその製造方法 | |
JPH0643429B2 (ja) | 高度に結晶性のナトリウムセフオペラゾンの製法 | |
US5144050A (en) | Ruthenium(II)-BINAP diketonate complexes | |
JPH0528221B2 (zh) | ||
EP3059226A1 (en) | 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride crystal | |
DE69804525T2 (de) | Chirale Träger und deren Verwendung in der Hertsellung oder Trennung von Enantiomeren | |
JPH02229198A (ja) | カリックスアレーン誘導体 | |
CN1176895C (zh) | 制备山梨酸的方法 | |
Uson et al. | Neutral bis (pentafluorophenyl) triphenylarsinegold (III) complexes | |
CN1028029C (zh) | 聚酰胺或聚酯酰胺热熔胶粉的制造方法 | |
US3057678A (en) | Preparation of zirconyl chloride octahydrate | |
DE3739174A1 (de) | Kondensierte acetessigsaeureester-titanchelate und verfahren zu deren herstellung | |
CN1044455A (zh) | 2,2,-二(1,6,7-三羟基-3-甲基-5-异丙基-8-萘甲醛)的纯化方法 | |
DE2461470A1 (de) | Polymere alkoxide auf der basis von hydroxyalkylmethacrylaten und ihr herstellungsverfahren | |
DE3137840A1 (de) | Zirkonmethacrylat, verfahren zu seiner herstellung und anwendung als vernetzungsmittel | |
KR100240479B1 (ko) | 금 카르복실산염과 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination |